Your annual health check says everything is “normal.”
So you move on.
Back to work. Back to meetings. Back to travel. Back to the next target.
But here’s the question worth asking:
How much does “normal” actually tell you about your cardiovascular risk?
If you run a business, you probably wouldn’t make an important decision using one number.
You look at revenue. You track cash flow. You watch margins.
You look for trends before they become problems.
Your cardiovascular health deserves the same level of attention.
A standard health check and lipid panel remain important. But they may not answer every question about your cardiovascular risk.
There are five additional cardiovascular biomarkers worth discussing with your physician:
ApoB. Lp(a). hs-CRP. HbA1c. Triglycerides.
They don’t replace the basics. They help complete the picture.
ApoB: How Many Atherogenic Particles Are Actually There?
Most people know their LDL cholesterol. Far fewer know their ApoB.
And that difference can matter.
LDL-C tells you how much cholesterol the LDL particles carry inside of them. ApoB helps estimate how many circulating atherogenic particles can contribute to atherosclerosis.
Think of it this way:
LDL-C tells you how much cargo is being transported.
ApoB tells you how many vehicles are carrying it.
Those numbers usually move together. But sometimes they don’t.
Two people can have the same LDL-C while carrying very different numbers of atherogenic particles. This discordance can be particularly relevant when triglycerides are elevated or when diabetes and other cardiometabolic abnormalities are present.
The executive takeaway : Knowing your LDL-C is important. Knowing your ApoB may add another layer to the story.
Lp(a): The Risk Factor You May Have Inherited
Here is one of the more surprising things about cardiovascular risk:
You can exercise regularly. Eat well. Maintain a healthy weight. Look fit. And still have an important inherited cardiovascular risk factor.
That factor is Lipoprotein(a), or Lp(a).
Lp(a) is largely determined by genetics, and when elevated, it is associated with increased risk of atherosclerotic cardiovascular disease and calcific aortic valve disease.
Lp(a) usually isn’t something you need to check every year. For most adults, measuring it once can provide important information for the long term. The 2026 ACC/AHA guideline recommends measuring Lp(a) at least once in adulthood.
The question to ask is “Do I know my Lp(a)?”
If the answer is no, it may be worth discussing with your physician.
hs-CRP: What About Inflammation?
We often talk about cardiovascular disease as a cholesterol problem. But atherosclerosis is more complicated than that. Inflammation also plays an important role.
High-sensitivity C-reactive protein (hs-CRP) indicates systemic inflammatory risk. Persistently high hs-CRP is recognized as a cardiovascular risk enhancer in the 2026 ACC/AHA guideline.
But there is an important caveat. An elevated hs-CRP does not mean you have coronary artery disease.
CRP can rise because of infection, inflammatory conditions, injury and other factors. So don’t interpret one abnormal result in isolation.
The executive takeaway: A biomarker can identify risk. It cannot diagnose disease by itself.
Context matters.
HbA1c: Your Metabolic Trend May Matter More Than One Glucose Reading
You probably know your cholesterol. But do you know what your HbA1c has been doing over the last several years?
HbA1c provides an estimate of average blood glucose exposure over approximately the previous two to three months. It can help identify normal glucose regulation, prediabetes, diabetes and changes in glycemic control over time.
Why does this matter for your heart?
Because insulin resistance, diabetes, visceral adiposity, hypertension and dyslipidemia often travel together. And metabolic dysfunction can develop well before someone feels unwell.
That is why the trend can be more useful than simply asking: “Is my glucose normal today?”
Ask instead: “Where is my metabolic health heading?”
Triglycerides: The Number You May Be Underestimating
Look at a typical lipid panel.
LDL gets the attention. HDL gets discussed. Triglycerides?
Often ignored.
But high triglycerides can be associated with insulin resistance, visceral adiposity, diabetes, excess alcohol intake, certain dietary patterns, metabolic syndrome and increased remnant lipoproteins.
They can also provide clues when LDL-C doesn’t tell the complete story.
For example, someone may have an LDL-C that looks reasonably controlled while still having an unexpectedly high number of ApoB-containing particles.
The takeaway: Don’t look at one number in isolation. Look at the pattern.
So Why Isn’t LDL-C on This List?
This is deliberate.
It isn’t because LDL-C is unimportant. It’s quite the opposite.
LDL-C remains central to cardiovascular risk assessment and lipid-lowering therapy.
The reason it isn’t on this list is simple: Most people already have it measured.
The purpose of these five biomarkers is to ask questions that a standard lipid panel may leave unanswered.
Instead of asking only: “What is my LDL?”
A better conversation might be: “How many atherogenic particles do I have? What is my inherited Lp(a) risk? What does my metabolic profile look like? And are there other risk factors that should change how we approach prevention?”
That’s a very different conversation.
One More Important Point: These Numbers Are Not the Disease
This distinction is critical.
A biomarker is a risk marker. It is not a direct measurement of coronary plaque. You can have reassuring biomarkers and still develop atherosclerosis. You can also have abnormal biomarkers without having advanced coronary disease.
That is why cardiovascular risk needs to be interpreted alongside factors such as:
- Age
- Blood pressure
- Smoking
- Kidney function
- Family history
- Body composition
- Physical activity
- Diet
- Sleep
- Fitness
- Medical history
- And, in selected patients, cardiovascular imaging
The goal isn’t to order every test available. The goal is to measure information that can actually change how we understand and manage risk.
The Executive Health Question We Should Ask More Often
If you’re in your 40s or 50s, feel healthy, exercise and perform at a high level, cardiovascular disease can feel like someone else’s problem.
You have no symptoms. Your annual physical looks fine. You feel great. But atherosclerosis develops over decades. And that’s precisely why prevention matters.
The opportunity isn’t to wait until something goes wrong. It’s to understand your risk while there is still time to influence its trajectory.
So the next time you receive your health report, don’t just ask: “Is everything normal?”
Ask: “Do I understand my cardiovascular risk well enough to know what I should optimize?”
That is a much better question.
Five Numbers Worth Discussing With Your Physician
ApoB
Helps characterize atherogenic particle burden.
Lp(a)
Identifies an important largely inherited cardiovascular risk factor and generally needs to be measured only once in adulthood.
hs-CRP
Can help identify persistent systemic inflammatory risk when interpreted in the right clinical context.
HbA1c
Provides a longer-term view of glycemic and cardiometabolic health.
Triglycerides
Can provide insight into both lipid and metabolic risk.
These aren’t substitutes for a comprehensive cardiovascular evaluation.
They’re pieces of a much larger puzzle.
From Annual Screening to Cardiovascular Optimization
At Pulse Perfect, Cardiovascular Optimization & Longevity, the approach is straightforward:
Measure what matters.
Understand what it means.
Intervene where appropriate.
Then measure whether you’re moving in the right direction.
For some people, routine screening may be appropriate. For others, particularly those with significant family history, metabolic disease, abnormal biomarkers or other risk enhancers, a deeper assessment may provide clinically useful information.
Preventive cardiology isn’t about ordering every possible test. It’s about asking better questions earlier.
Because when it comes to cardiovascular disease, some of the most valuable information is the information we discover before symptoms begin.
This article is for educational purposes and is not individualized medical advice.